A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.
Vijaya Raj BhattValerie K ShostromHannah K ChoeBetty K HamiltonKrishna GundaboluLori J ManessVirender KumarRam I MahatoLynette M SmithTaiga NishihoriStephanie J LeePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The use of ruxolitinib was associated with relatively high rates of skin/joint responses and overall cGVHD responses, improvement in patient-reported outcomes, low NRM, and high FFS in patients with refractory sclerotic cGVHD. Ruxolitinib offers an effective treatment option for refractory sclerotic cGVHD.